CAV1 and systemic sclerosis: Given that CSD, by acting as a surrogate for caveolin-1, reverses the enhanced ability of AA and SSc monocytes to differentiate into fibrocytes (Reese et al., 2014b), we hypothesized that CSD might also reverse the decreased ability of AIM-treated AA and SSc monocytes to differentiate into ALCs.